The FDA’s STeP program recognizes technologies with strong potential to improve patient safety.
Symphera has been accepted into the FDA’s Safer Technologies Program (STeP), a pathway designed to support the development of medical technologies that may meaningfully improve safety during clinical procedures. The selection acknowledges Symphera’s potential to enhance consistency and workflow control through automated instrument switching.
Participation in STeP gives Symphera enhanced interaction with the FDA as the company advances engineering work, risk-management activities, and upcoming pre-clinical studies. The collaboration will help ensure the system aligns with rigorous safety expectations from the earliest stages of development.